Nevirapine Resistance in HIV-infected Infants

Infants in low-resource settings are often treated with nevirapine to prevent HIV transmission. The PEPI-Malawi study showed that those infants treated with 14 weeks of nevirapine showed high rates of resistance to the drug that persisted for up to twelve months. Those treated with nevirapine plus AZT showed slightly (but not significantly) lower rates of resistance.

Citation:
Fogel J, Hoover DR, Sun J, Mofeson LM, Fowler MG, Taylor AW, Kumwenda N, Taha TE, Eshelman SH. Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis. AIDS. 2011 Apr 24;25(7):911-917.

Original Article (subscription may be required)

Abstract